ANTX

AN2 Therapeutics, Inc. (ANTX) ESG Analysis Analysis (2026)

Invetso Score: 5/10 — Balanced · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Environmental

Score: 4.5 (Moderate)

ANTX’s environmental risk is moderate due to its low operational footprint, but the lack of disclosure and formal sustainability commitments limits its standing versus peers with more robust ESG programs.

Social

Score:

ANTX’s social profile is moderate, reflecting standard compliance in clinical operations but limited transparency and formal programs in workforce and community engagement.

Governance

Score:

ANTX’s governance is moderate, with no major red flags but also no evidence of advanced practices or strong board independence relative to more mature peers.

Overall Score

Score:

ANTX’s ESG profile is moderate across all pillars, reflecting low operational risk but limited disclosure, formalization, and board independence. The company’s early-stage status explains some gaps, but it trails best-in-class biotech peers on transparency and proactive ESG management.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on AN2 Therapeutics, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →